Coherus Biosciences and Junshi Biosciences announced positive interim from the phase 3 CHOICE-01 trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.